Sporotrichosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Matt Pijoan (talk | contribs) No edit summary |
Matt Pijoan (talk | contribs) No edit summary |
||
Line 14: | Line 14: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Uncomplicated cutaneous | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Uncomplicated cutaneous | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Itraconazole]] 200 mg PO qd | * [[Itraconazole]] 200 mg PO qd | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | ||
* [[Itraconazole]] 200 mg PO bid, {{Or}} | * [[Itraconazole]] 200 mg PO bid, {{Or}} | ||
* [[Terbinafine]] 500 mg PO bid, {{Or}} | * [[Terbinafine]] 500 mg PO bid, {{Or}} | ||
Line 22: | Line 22: | ||
* [[Fluconazole]] 400-800 mg PO qd, {{Or}} | * [[Fluconazole]] 400-800 mg PO qd, {{Or}} | ||
* Local hyperthermia | * Local hyperthermia | ||
|Continue treatment for 2-4 weeks after lesions resolve. | | style="padding: 5px 5px; background: #F5F5F5;" |Continue treatment for 2-4 weeks after lesions resolve. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Osteoarticular | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Osteoarticular | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd until symptom resolution | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd until symptom resolution | ||
Line 33: | Line 33: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Pulmonary | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Pulmonary | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Limposomal [[amphotericin B]] 3-5 mg/kg IV qd '''<u>THEN</u>''' | * Limposomal [[amphotericin B]] 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid upon symptom resolution | * [[Itraconazole]] 200 mg PO bid upon symptom resolution | ||
Line 42: | Line 42: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meningeal | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meningeal | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid upon symptom resolution | * [[Itraconazole]] 200 mg PO bid upon symptom resolution | ||
Line 51: | Line 51: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Dissimated | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Dissimated | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid. | * [[Itraconazole]] 200 mg PO bid. | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid upon symptom resolution | * [[Itraconazole]] 200 mg PO bid upon symptom resolution | ||
Line 60: | Line 60: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in pregnant women | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in pregnant women | ||
| colspan="2" | | | style="padding: 5px 5px; background: #F5F5F5;" | colspan="2" | | ||
* Treat with limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | * Treat with limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd only for severe cases of sporotrichosis '''<u>OR</u>''' | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd only for severe cases of sporotrichosis '''<u>OR</u>''' | ||
Line 68: | Line 68: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in Children | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in Children | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Itraconazole]] 6-10 mg PO qd to a max of 400 mg PO qd for mild cases '''<u>OR</u>''' | * [[Itraconazole]] 6-10 mg PO qd to a max of 400 mg PO qd for mild cases '''<u>OR</u>''' | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg IV qd for severe cases | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd for severe cases | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Potassium iodide|SSKI]] increasing doses equivalent to half the adult dose, continuing treatment for 2-4 weeks after resolution of symptoms. | * [[Potassium iodide|SSKI]] increasing doses equivalent to half the adult dose, continuing treatment for 2-4 weeks after resolution of symptoms. | ||
| | | |
Revision as of 17:38, 13 January 2016
Sporotrichosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Sporotrichosis medical therapy On the Web |
American Roentgen Ray Society Images of Sporotrichosis medical therapy |
Risk calculators and risk factors for Sporotrichosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]
Treatment
Form | Primary Line of Treatment | Alternative Treatment | Remarks/Other |
---|---|---|---|
Uncomplicated cutaneous |
|
style="padding: 5px 5px; background: #F5F5F5;"
|
Continue treatment for 2-4 weeks after lesions resolve. |
Osteoarticular |
|
|
For a total of 12 months, switch to Itraconazole after resolution/end of treatment. |
Pulmonary |
|
|
Treat less sever cases with a 12 month regimen of Itraconazole. |
Meningeal |
|
|
Precise length of amphotericin B treatment varies. Suppressive treatment with Itraconazole is necessary. |
Dissimated |
|
|
Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with Itraconazole is necessary. |
Sporotrichosis in pregnant women | colspan="2" |
|
It is preferable to defer treatment in uncomplicated cases. | |
Sporotrichosis in Children |
|
|
References
- ↑ Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.